Scopus BioPharma

Scopus BioPharma Inc. is a biopharmaceutical company dedicated to developing innovative therapeutics based on significant scientific and medical advancements from renowned research institutions. The company's primary focus is on immuno-oncology, particularly through its lead drug candidate, a targeted gene therapy aimed at treating multiple cancers. In addition to this, Scopus is exploring new chemical entities to address serious diseases with considerable unmet needs, such as systemic sclerosis. The company also emphasizes the endocannabinoid system, developing therapeutics that utilize synthetically-produced cannabinoids rather than plant-derived compounds. Among its product candidates are CO-sTiRNA, a STAT3 inhibitor gene therapy, and MRI-1867, which further exemplify its commitment to advancing treatment options in the biopharmaceutical landscape.